GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ananda Pharma PLC (STU:1FX) » Definitions » Common Stock

Ananda Pharma (STU:1FX) Common Stock : €6.71 Mil (As of Jul. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Ananda Pharma Common Stock?

Ananda Pharma's quarterly common stock increased from Jul. 2022 (€1.93 Mil) to Jan. 2023 (€2.66 Mil) and increased from Jan. 2023 (€2.66 Mil) to Jul. 2023 (€6.71 Mil).

Ananda Pharma's annual common stock increased from Jan. 2021 (€1.04 Mil) to Jan. 2022 (€1.91 Mil) and increased from Jan. 2022 (€1.91 Mil) to Jan. 2023 (€2.66 Mil).


Ananda Pharma Common Stock Historical Data

The historical data trend for Ananda Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ananda Pharma Common Stock Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23
Common Stock
0.74 0.99 1.04 1.91 2.66

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.86 1.91 1.93 2.66 6.71

Ananda Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Ananda Pharma Business Description

Traded in Other Exchanges
N/A
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is focused on the development of cannabinoid therapies for the treatment of a range of complex conditions. The company is developing NHS-approved and MHRA-licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure.

Ananda Pharma Headlines

No Headlines